Shizukaol B exerts anti-inflammatory effects in LPS-activated microglia partly by modulating JNK-AP-1 signaling pathway; it also shows significant anti-neuroinflammatory effects by inhibiting nitric-oxide (NO) production in lipopolysaccharide (LPS)-stimul
1. Shizukaol C shows anti-HIV-1 replication activities in both wild-type HIV-1 and two NNRTIs-resistant strains. 2. Shizukaol C has significant cytotoxicities against C8166 cells.
Shizukaol D exerts a growth inhibition effect on liver cancer cells in a dose- and time-dependent manner by modulating wnt signalling pathway. Shizukaol D may be used to treat metabolic syndrome, it induces mitochondrial dysfunction by depolarizing the mitochondrial membrane and suppressing energy production, which may result in AMPK activation.
Cycloshizukaol A prevents monocyte adhesion to HUVEC through the inhibition of cell adhesion molecules expression stimulated by TNF-alpha, it inhibits PMA-induced homotypic aggregation of HL-60 cells without cytotoxicity with MIC values of 0.9 microM.